The ten most common adverse drug reactions (ADRs) in oncology patients: Do they matter to you?

Supportive Care in Cancer

Volumn 12, Issue 9, 2004, Pages 626-633

  Lau, Phyllis M ^a   Stewart, Kay ^a   Dooley, Michael ^a,b  

^a MONASH UNIVERSITY   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

Adverse drug reactions; Cancer patients; Causality; Predictability; Preventability; Severity

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; ADVERSE DRUG REACTION; AGED; ALOPECIA; ANOREXIA; AUSTRALIA; BONE MARROW SUPPRESSION; CONSTIPATION; DIARRHEA; DISEASE SEVERITY; DROWSINESS; FATIGUE; FEMALE; HOSPITAL ADMISSION; HUMAN; INCIDENCE; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; MEDICAL RECORD; MUCOSA INFLAMMATION; NAUSEA; ONCOLOGY; PERCEPTION; PREDICTION; PRIORITY JOURNAL; REVIEW; SKIN TOXICITY; SYMPTOM; VOMITING; WELLBEING;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CANCER CARE FACILITIES; DRUG INTERACTIONS; DRUG MONITORING; DRUG TOXICITY; FEMALE; HUMANS; INTERVIEWS; MALE; MIDDLE AGED; NEOPLASMS; VICTORIA;

EID: 4644299135     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-004-0622-5     Document Type: Review

References (28)

1. American Hospital Formulary Service drug information (1984) Board of Directors of the American Society of Hospital Pharmacists, Bethesda
2. Audit Commission (2001) A spoonful of sugar-medicines management in NHS hospitals. Audit Commission, London
3. Australian adverse drug reactions bulletin (1998) Australian Adverse Drug Reaction Advisory Committee (ADRAC)
4. Australian prescription products guide (2000) 29th edn. Australian Pharmaceutical Publishing
5. Bates D, Leape L, Petrycki S (1993) Incidence and preventability of adverse drug events in hospitalized adults. J Gen Intern Med 8:289-294
6. Council for International Organisation for Medical Science (CIOMS) (1994) WGI, Guidelines for preparing core clinical-safety information on drugs. Council for International Organisation for Medical Sciences, Geneva
7. Clinical Oncological Society of Australia (2002) Optimising cancer care in Australia. The Cancer Council Australia and the National Cancer Council Initiative, Melbourne, pp 1-122
8. Coates AS, Abraham SB, Kaye T et al (1983) On the receiving end-patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 19:203-208
9. Dewland P, Dewland J (1999) At the coalface, but on the receiving end. J Med Ethics 25:541-546
10. Dormann H, Muth-Selbach U, Krebs S et al (2000) Incidence and costs of adverse drug reactions during hospitalisation: computerised monitoring versus stimulated spontaneous reporting. Drug safety 22:161-168
11. Dukes J, Chalker M, Leuwer PKM et al (2000) Meyler's side effects of drugs, 14th edn. Elsevier, New York
12. Fisher S, Kent TA, Bryant SG (1995) Postmarketing surveillance by patient self-monitoring: preliminary data for sertraline versus fluoxetine. J Clini Psych 56:288-296
13. Foddy W (1994) Constructing questions for interviews and questionnaires. Theory and practice in social research. Cambridge University Press
14. Green CF, Mottram DR, Rowe PH, Pirmohamed M (2000) Adverse drug reactions as a cause of admission to an acute medical assessment unit: a pilot study. J Clin Pharm Ther 25:355-361
15. Griffin AM, Butow PN Coates AS et al (1996) On the receiving end. V: Patient perceptions of the side effects of cancer chemotherapy in 1993. An Oncol 7:189-195
16. Jarernsiripornkul N, Krska J, Capps PA et al (2002) Patient reporting of potential adverse drug reactions: a methodological study. Br J Clin Pharmacol 53:318-325
17. Mjorndal T, Boman MD, Hagg S et al (2002) Adverse drug reactions as a cause for admissions to a department of internal medicine. Pharmacoepidemiol Drug Saf 11:65-72
18. Naranjo C, Busto U, Sellars E et al (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30:239-245
19. National hospital morbidity data collection - Australia (excluding NT) (1992-1993)
20. Pon D (1996) Service plans and clinical interventions targeted by the oncology pharmacist. Pharm Pract Manag 16:18-30
21. PREMEDLINE and MEDLINE version: rel 6.1.0, source ID 1.7672.1.63
22. Roughead EE, Gilbert AL, Primrose JG, Sansom LN (1998) Drug-related hospital admissions: a review of Australian studies published 1988-1996. Medi J Aust 168:405-408
23. Schumock G, Thornton J (1992) Focusing on the preventability of adverse drug reactions. Hosp Pharm 27:538
24. Tegeder I, Levy M, Muth-Selbach U et al (1999) Retrospective analysis of the frequency and recognition of adverse drug reactions by means of automatically recorded laboratory signals. Br J Clin Pharmacol 47:557-564
25. Thomson MICROMEDEX. MICROMEDEX(R) Health-care Series Vol. 117. http://micromedex.hcn.net.au/mdx-full/. Cited 19 Oct 2003
26. White TJ, Arakelian A, Rho JP (1999) Counting the costs of drug-related adverse events. Pharmacoeconomics 15:445-458
27. Wilson R, Runciman W, Gibberd R et al (1995) Quality in Australian health care study. Med J Aust 163:458-471
28. World Health Organization (1999) Common toxicity criteria (CTC). 1 August 1999